Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology

Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology

Abstract Background Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia...

Full description

Bibliographic Details
Main Authors: Bahira Shahim, Viveca Gyberg, Dirk De Bacquer, Kornelia Kotseva, Guy De Backer, Oliver Schnell, Jaakko Tuomilehto, David Wood, Lars Rydén
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Impaired glucose tolerance
Screening
FINDRISC
Dyslipidaemia
Hypertension
Online Access:http://link.springer.com/article/10.1186/s12933-018-0665-4

Internet

http://link.springer.com/article/10.1186/s12933-018-0665-4

Similar Items